Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 3/20 | 0.35 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.35 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28041416 | 0.97 | APOBEC3A (0.42) | APOBEC3AAPOBEC3GCHRNB4CHRNA3CHRNA7 | |
| Bromide SCHEMBL2708611 | 0.97 | APOBEC3A (0.42) | APOBEC3AAPOBEC3GCHRNB4CHRNA3CHRNA7 | |
| Bromide SCHEMBL28157103 | 0.97 | APOBEC3A (0.42) | APOBEC3AAPOBEC3GCHRNB4CHRNA3CHRNA7 | |
| SCHEMBL124830 | 0.97 | APOBEC3A (0.46) | APOBEC3AAPOBEC3GCHRNB4CHRNA3CHRNA7 | |
| Bromide SCHEMBL28157102 | 0.95 | APOBEC3A (0.40) | APOBEC3AAPOBEC3GCHRNB4CHRNA3CHRNA7 | |
| Bromide SCHEMBL28041414 | 0.95 | APOBEC3A (0.40) | APOBEC3AAPOBEC3GCHRNB4CHRNA3CHRNA7 | |
| Water SCHEMBL188046 | 0.94 | APOBEC3A (0.43) | APOBEC3AAPOBEC3GCHRNB4CHRNA3CHRNA7 | |
| SCHEMBL9752206 | 0.94 | APOBEC3A (0.43) | APOBEC3AAPOBEC3GCHRNB4CHRNA3CHRNA7 | |
| Iodide SCHEMBL2353165 | 0.94 | APOBEC3A (0.50) | APOBEC3AAPOBEC3GCHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL125419 | 0.94 | APOBEC3A (0.43) | APOBEC3AAPOBEC3GCHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102161-A2 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | Pfizer Products Incorporated (US) | 2009-09-23 | — | — | EP | claimed |
| US-20080177077-A1 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | PFIZER, INC. | 2008-07-24 | — | — | US | claimed |
| WO-2008072079-A2 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | PFIZER PRODUCTS INC. (US) | 2008-06-19 | — | — | WO | claimed |
| US-9434684-B2 | Oxime-substituted amide compound and pest control agent | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-09-06 | — | — | US | disclosed |
| US-20150210630-A1 | OXIME-SUBSTITUTED AMIDE COMPOUND AND PEST CONTROL AGENT | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| EP-2102161-B1 | Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6-methyl- 2-oxopyridin-1(2H)-yl)-N,4-dimethylbenzamide | PFIZER PROD INC (US) | 2012-05-02 | — | — | EP | disclosed |
| US-7906536-B2 | Halogenation of methyl 3-(4-hydroxy-6-methyl-2-oxopyridin-1(2H)-yl)-4-methylbenzoate or derivative; reacting with benzyl halide in solvent and base; chemical intermediates of 4-hydroxy-6-methylpyranone and methyl-3-amino-4-methyl benzoate; amidation, etherification, esterification; p38 kinase inhibitor | PFIZER INC (US) | 2011-03-15 | — | — | US | disclosed |
| CN-101611006-A | 3-(4-(2,4-difluoro benzyloxy)-3-bromo-6-methyl-2-oxo pyridine-1 (2H)-yl)-N, the preparation method of 4-dimethyl benzamide | PFIZER PROD INC (US) | 2009-12-23 | — | — | CN | disclosed |
| EP-2102161-A2 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | Pfizer Products Incorporated (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20080177077-A1 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | PFIZER, INC. | 2008-07-24 | — | — | US | disclosed |
| WO-2008072079-A2 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | PFIZER PRODUCTS INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| EP-1542680-B1 | 1, 4, 5-SUBSTITUTED 1, 2-DIHYDRO-PYRAZOL-3-ONE AND 3-ALKOXY-1H-PYRAZOLE DERIVATIVES AS TNF-ALPHA AND INTERLEUKIN LOWERING AGENTS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC (US) | 2007-03-07 | — | — | EP | disclosed |
| US-6967254-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2005-11-22 | — | — | US | disclosed |
| EP-1542680-A1 | 1, 4, 5-SUBSTITUTED 1, 2-DIHYDRO-PYRAZOL-3-ONE AND 3-ALKOXY-1H-PYRAZOLE DERIVATIVES S TNF-ALPHA AND INTERLEUKIN LOWERING AGENTS FOR THE TREATMENT OF INFLAMMATIONS | Amgen Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040058918-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2004-03-25 | — | — | US | disclosed |
| WO-2004022055-A1 | 1, 4, 5-SUBSTITUTED 1, 2-DIHYDRO-PYRAZOL-3-ONE AND 3-ALKOXY-1H-PYRAZOLE DERIVATIVES S TNF-ALPHA AND INTERLEUKIN LOWERING AGENTS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC. (US) | 2004-03-18 | — | — | WO | disclosed |
| US-H1427-H | Treating cancer by administering flavonoid immunomodulator with interleukin-2 | BRIET PHILLIPE (FR) | 1995-04-04 | — | — | US | disclosed |
| EP-0341104-B1 | Substituted flavonoid compounds, their salts, their manufacture and medicines containing these materials | MERCK PATENT GMBH (DE) | 1993-12-29 | — | — | EP | disclosed |
| US-5116954-A | Antitumor agents | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1992-05-26 | — | — | US | disclosed |
| EP-0341104-A2 | Substituted flavonoid compounds, their salts, their manufacture and medicines containing these materials | MERCK PATENT GmbH (DE) | 1989-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058918-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MAPT, HMGB1 | ACHE 217/4885CHRM3 276/4885CHRM2 290/4885 |
| US-20150210630-A1 | OXIME-SUBSTITUTED AMIDE COMPOUND AND PEST CONTROL AGENT | CHRM1, CHRM2, CHRM4 | ACHE 50/4885CHRM3 4/4885CHRM2 2/4885 |
| US-20080177077-A1 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | CYP4X1, CYP4B1, KDM4B | ACHE 809/4885CHRM3 131/4885CHRM2 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.